A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point (Q6642064)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point |
scientific article; zbMATH DE number 7947987
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point |
scientific article; zbMATH DE number 7947987 |
Statements
A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point (English)
0 references
21 November 2024
0 references
Bayesian adaptive design
0 references
dose finding
0 references
immunotherapy
0 references
phase I--II trials
0 references
risk-benefit trade-off
0 references
